Transgenic Pig Model for Cystic Fibrosis Research
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current approaches to treating cystic fibrosis lack effective animal models that accurately replicate human disease pathology, limiting the development of new treatments and therapies.
Innovation Solution
The creation of transgenic, large non-human animal models, such as pigs, with targeted mutations in genes associated with cystic fibrosis, including the CFTR gene, to mimic human disease conditions, allowing for the evaluation of therapeutic agents and understanding disease mechanisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If transgenic animal models are created to accurately replicate human cystic fibrosis pathology, then the physiological relevance and therapeutic testing capability are improved, but the device complexity and manufacturing difficulty increase
Solution Approach 1:
The patent creates transgenic animal models that copy human CFTR gene mutations (such as ΔF508) to replicate the molecular and physiological mechanisms of human cystic fibrosis. This copying approach allows the animal models to accurately reproduce human disease pathology, including defective chloride channel function, abnormal mucus secretion, and organ-specific manifestations, thereby resolving the contradiction between model accuracy and complexity by using genetic replication rather than phenomenological simulation
Solution Approach 2:
The patent introduces specific genetic parameter changes (mutations in the CFTR gene) into animal models to alter their physiological parameters and match human cystic fibrosis characteristics. By changing the genetic parameters (DNA sequence, protein folding, channel gating) rather than attempting to replicate all disease symptoms, the patent achieves high disease model accuracy while managing the complexity through targeted genetic modification rather than comprehensive system replication
2Reliability
If large non-human animal models are used instead of mice, then the physiological relevance for therapeutic testing is improved, but the ease of manufacture and cost increase
Solution Approach 1:
The patent develops transgenic large animal models (pigs, sheep, goats) that serve multiple functions: they replicate human CF pathology, enable therapeutic agent testing, allow study of organ-specific disease manifestations, and provide a platform for evaluating both pharmacological and gene therapy approaches. This multi-functionality justifies the increased manufacturing complexity by consolidating multiple research needs into a single model system, replacing the need for multiple different model organisms
Solution Approach 2:
The patent employs preliminary genetic modification of embryonic cells or fertilized eggs to establish the desired CFTR mutation before animal development begins. This preliminary action ensures that the genetic defect is present from conception, allowing the animals to naturally develop human-like cystic fibrosis pathology without requiring post-birth interventions or complex conditioning protocols, thereby simplifying the overall manufacturing process despite the use of large animals
Data Source
AI summary
The present invention provides transgenic, large non-human animal models of diseases and conditions, as well as methods of making and using such animal models in the identification and characterization of therapies for the diseases and conditions.